Active Biotech says first amended — protocol cohort clears safety review in HOVON 172 MF tasquinimod trial
Active Biotech reported the first three-patient safety cohort completed a six-week evaluation in the HOVON 172 MF tasquinimod study. Results have been presented now as an interim safety update from patients enrolled under an amended dosing protocol. One serious adverse event met dose-limiting toxicity criteria, resolve